TP53 and breast cancer: For instance, one study including 450 BC patients receiving anthracycline/taxane-based NAC indicated that TP53 mutations were not statistically associated with pCR (27); however, a meta-analysis suggested that altered TP53 gene was related to better response rates, and this association remained significant when BC patients were stratified according to their NAC regimens (28).